	US 11,717,562 B2
	Method and composition for treating arginase 1 deficiency
Scott W. Rowlinson, Austin, TX (US); Anthony G. Quinn, Gloucester, MA (US); Ann Lowe, Austin, TX (US); and David Lowe, Austin, TX (US)
Assigned to AERase, Inc., Austin, TX (US)
Filed by AERase, Inc., Austin, TX (US)
Filed on Dec. 5, 2018, as Appl. No. 16/210,248.
Claims priority of provisional application 62/594,747, filed on Dec. 5, 2017.
Claims priority of provisional application 62/725,612, filed on Aug. 31, 2018.
Claims priority of provisional application 62/745,000, filed on Oct. 12, 2018.
Prior Publication US 2019/0167770 A1, Jun. 6, 2019
Int. Cl. A61K 38/00 (2006.01); A61K 47/00 (2006.01); A61K 38/50 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61K 47/60 (2017.01); A61K 38/51 (2006.01)

CPC A61K 38/50 (2013.01) [A61K 9/0019 (2013.01); A61K 38/51 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61K 48/005 (2013.01); A61P 3/00 (2018.01); C12Y 305/03001 (2013.01)]

46 Claims

1. A method of treating Arginase 1 (ARG1) deficiency (ARG1-D) in a human patient in need thereof, the method comprising weekly administering a human arginase I having a cobalt metal cofactor to the patient, wherein the human arginase I is administered either intravenously at a weekly dose of about 0.005 to about 0.15 mg/kg or intramuscularly or subcutaneously at a weekly dose of about 0.01 to about 0.15 mg/kg.